RT-CGM was dominant in both insulin-treated subgroups, improving patient outcomes while reducing healthcare costs. These findings highlight the potential value of RT-CGM for broad reimbursement in Australia and the importance of addressing inequities in glycemic management, particularly among Indigenous Australians and younger individuals with T2D.
Alshannaq et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: